PMID- 28790806
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1177-889X (Print)
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 11
DP  - 2017
TI  - Perceptions of patients with rheumatic diseases on the impact on daily life and 
      satisfaction with their medications: RHEU-LIFE, a survey to patients treated with 
      subcutaneous biological products.
PG  - 1243-1252
LID - 10.2147/PPA.S137052 [doi]
AB  - OBJECTIVE: The aim of this study was to explore perceptions of patients with 
      rheumatic diseases treated with subcutaneous (SC) biological drugs on the impact 
      on daily life and satisfaction with current therapy, including preferred 
      attributes. METHODS: A survey was developed ad hoc by four rheumatologists and 
      three patients, including Likert questions on the impact of disease and treatment 
      on daily life and preferred attributes of treatment. Rheumatologists from 50 
      participating centers were instructed to handout the survey to 20 consecutive 
      patients with rheumatoid arthritis (RA), axial spondyloarthritis (ax-SpA), or 
      psoriatic arthritis (PsA) receiving SC biological drugs. Patients responded to 
      the survey at home and sent it to a central facility by prepaid mail. RESULTS: A 
      total of 592 patients returned the survey (response rate: 59.2%), 51.4% of whom 
      had RA, 23.8% had ax-SpA, and 19.6% had PsA. Patients reported moderate-to-severe 
      impact of their disease on their quality of life (QoL) (51.9%), work/daily 
      activities (49.2%), emotional well-being (41.0%), personal relationships (26.0%), 
      and close relatives' life (32.3%); 30%-50% patients reported seldom/never being 
      inquired about these aspects by their rheumatologists. Treatment attributes 
      ranked as most important were the normalization of QoL (43.6%) and the relief 
      from symptoms (35.2%). The satisfaction with their current antirheumatic therapy 
      was high (>80% were "satisfied" or "very satisfied"), despite moderate/severe 
      impact of disease. CONCLUSION: Patients with rheumatic diseases on SC biological 
      therapy perceive a high disease impact on different aspects of daily life, 
      despite being highly satisfied with their treatment; the perception is that 
      physicians do not frequently address personal problems. Normalization of QoL is 
      the most important attribute of therapies to patients.
FAU - Gonzalez, Carlos M
AU  - Gonzalez CM
AD  - Department of Rheumatology, Gregorio Maranon Hospital.
FAU - Carmona, Loreto
AU  - Carmona L
AD  - Instituto de Salud Musculoesqueletica, Madrid.
FAU - de Toro, Javier
AU  - de Toro J
AD  - Department of Rheumatology, Hospital Universitario A Coruna, A Coruna.
FAU - Batlle-Gualda, Enrique
AU  - Batlle-Gualda E
AD  - Department of Rheumatology, Hospital Universitario de Sant Joan d'Alacant, 
      Alicante.
FAU - Torralba, Antonio I
AU  - Torralba AI
AD  - Coordinadora Nacional de Artritis.
FAU - Arteaga, Maria J
AU  - Arteaga MJ
AD  - Medical Affairs Department, Merck Sharp & Dohme, Madrid, Spain.
FAU - Cea-Calvo, Luis
AU  - Cea-Calvo L
AD  - Medical Affairs Department, Merck Sharp & Dohme, Madrid, Spain.
LA  - eng
PT  - Journal Article
DEP - 20170719
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
EIN - Patient Prefer Adherence. 2019 May 06;13:665. PMID: 31123395
PMC - PMC5530861
OTO - NOTNLM
OT  - biological drugs
OT  - emotional well-being
OT  - patient's satisfaction
OT  - quality of life
OT  - rheumatic diseases
COIS- Disclosure MJA and LC-C are full employees at Merck Sharp & Dohme (MSD) of Spain. 
      The rest of the authors received honoraria from MSD, Spain, as advisors for the 
      design, implementation, and data interpretation of the survey. CMG has received 
      honoraria for lectures for MSD, Spain. EB-G has served as a consultant for BMS, 
      Roche, and MSD, Spain, and has received honoraria for lectures or educational 
      presentations for Abbvie, UCB, Roche, Pfizer, and BMS. The authors report no 
      other conflicts of interest in this work.
EDAT- 2017/08/10 06:00
MHDA- 2017/08/10 06:01
PMCR- 2017/07/19
CRDT- 2017/08/10 06:00
PHST- 2017/08/10 06:00 [entrez]
PHST- 2017/08/10 06:00 [pubmed]
PHST- 2017/08/10 06:01 [medline]
PHST- 2017/07/19 00:00 [pmc-release]
AID - ppa-11-1243 [pii]
AID - 10.2147/PPA.S137052 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2017 Jul 19;11:1243-1252. doi: 10.2147/PPA.S137052. 
      eCollection 2017.